Searchable abstracts of presentations at key conferences in endocrinology

ea0022oc3.3 | Pituitary | ECE2010

Trauma severity, but not hypopituitarism, affects cognitive function after traumatic brain injury: a multi-center study in The Netherlands

Kokshoorn Nieke , Smit Jan , Nieuwlaat Willy-Anne , Biermasz Nienke , Bisschop Peter , Veldman Ronald Groote , Roelfsema Ferdinand , Franken Anton , Wassenaar Moniek , Tiemensma Jitske , Romijn Johannes , Pereira Alberto

Background: Hypopituitarism after traumatic brain injury (TBI) is considered to be a prevalent condition, and may affect quality of life (QoL) and cognitive function. However, the prevalence of hypopituitarism differs considerably among reported studies due to differences in definitions, endocrine assessments of hypopituitarism, and confounding factors, like timing of evaluation and the severity of the trauma.Aim: To evaluate the prevalence of hypopituit...

ea0070ep340 | Pituitary and Neuroendocrinology | ECE2020

The galant trial: a randomised placebo-controlled trial in patients with a gallium-68 dotatate pet positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size

Boertien Tessel M. , Drent M.L. , Booij Jan , Majoie Charles B.L.M. , Stokkel Marcel P.M. , Hoogmoed Jantien , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Veldman Ronald Groote , Tanck Michael W.T. , Fliers Eric , Bisschop Peter H.

Rationale: At present, there is no approved medical treatment for patients with clinically non-functioning pituitary adenoma. A number of open-label studies suggest that treatment with somatostatin analogues may prevent tumour progression in selected patients. In vivo assessment of somatostatin receptor status using 68Ga-DOTATATE PET could help to select patients responsive to treatment.Trial objective: To investigate the effect of the somatosta...